Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ty method

investments 188 5,612

Minority interest 463 3,912

Gain (loss) on investments in

equity securities (3) 775 12,788

Other (160) (525)

Investment income 14,870 16,219

Interest expense (1,655) (4,188)

Total other income (expenses) 14,481 33,818

Income (loss) before income taxes (1) 205,388 229,380

(Provision for) benefit from income

taxes (1) (60,117) (71,193)

Net income (loss) (1) $145,271 $158,187

Net income (loss) per share:

Basic $0.54 $0.60

Diluted (1,4) $0.52 $0.57

Weighted average shares outstanding:

Basic 267,276 263,476

Diluted (1,4) 285,208 279,924

(1) In accordance with the provisions of Financial Accounting Standards

Board, or FASB, Statement of Financial Accounting Standards No., or

FAS, 123R, "Share-Based Payment, an amendment of FASB Statement Nos.

123 and 95," we recorded pre-tax charges for stock-based compensation

expense and related tax benefits of:

Three Months Ended

March 31,

2008 2007

Cost of products and services sold $(6,514) $(5,896)

Selling, general and administrative


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Eckert & Ziegler Vitalea Science ... services to the pharmaceutical and biotech industry, has announced ... in the position of Director of Science & Technology. ... valuable experience in drug metabolism and bioanalysis to EZVS ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... The laboratory information management systems market is a rapidly ... advancements due to factors such as rising pressure to ... systems, and increasing government support for adoption of HCIT ... in the market focus on technological advancements to further ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... For the second month in a row,the capital markets succumbed ... day of the month the Dow dropped over 300 points ... time. Amid these,fears, biotech was dragged down with the Burrill ... and the Dow, which closed down,3%., "The biotech sector ...
... BEACH, Va., March 3 LifeNet Health,a leading ... This product has been engineered for anterior,cervical fusion ... The new VG1(R) Cervical Bio-implant was co-developed ... represented in the U.S. by DePuy,Spine., "VG1(R) ...
... Calif., March 3 ROBODOC, a Curexo,Technology Company, ... into a,major patent Cross licensing agreement. The terms ... In addition to its current surgical robotics ... 40,000 patents in IBM,S Global Portfolio,and particularly, IBM,s ...
Cached Biology Technology:Biotech Drops Amid Tough Markets in February 2Biotech Drops Amid Tough Markets in February 3LifeNet Health(R) Unveils New Biomedical Spine Implant 2ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Institutes of Health have identified a gene associated with ... attacks, irresistible bouts of sleep that can strike at ... has a known role in the immune system, which ... turns against the body,s own tissues, plays an important ...
... May 3, 2009 Ben W. Strowbridge, Ph.D, associate professor ... student in the neurosciences program at Case Western Reserve ... a form of synaptic memory in the olfactory bulb, ... of smell. Their study, entitled "Long-term plasticity of ...
... 2009 Two scientists whose work has led to new ... have been chosen to receive the 2009 March of Dimes ... and Louis M. Kunkel, Ph.D., will share the 2009 March ... and proteins that cause muscular dystrophy, a disorder in which ...
Cached Biology News:Genetic study confirms the immune system's role in narcolepsy 2Genetic study confirms the immune system's role in narcolepsy 3Neuroscientists discover long-term potentiation in the olfactory bulb 2Neuroscientists discover long-term potentiation in the olfactory bulb 3March of Dimes awards $250,000 prize to scientists unraveling the causes of muscular dystrophy 2
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
... Ek Adaptor encodes a T7 promoter, ... ATG translation initation codon, and an N-terminal ... 109 aa sequence that encodes thioredoxin. Fusion ... enhance solubility of many proteins that are ...
...
Biology Products: